발열이 동반된 호중구 감소증 환자에서 경험적 치료제로서 cefepime 단독요법과 ceftazidime 단독요법의 효과 비교 연구

이동현,김춘관,고지영,마주락,이가영,천상열,김봉석,노용호 대한화학요법학회 2002 대한화학요법학회지 Vol.20 No.3

발열이 동반된 호중구감소증 환자에서 초기경험적 치료제로서 cefepime은 선택될 수 있다.Cefepime 단독요법은 ceftazidime 단독요법과 비교하여 동등한 임상적 성공률을 보였으나, 향후 더 많은 환자를 대상으로 한 비교연구 및 자료의 보충이 필요하다 하겠다. Background : In view of the recent trend toward monotherapy in the treatment of bacterial infection, we evaluate the clinical efficacy and safety of cefepime versus ceftazidime for the empiric treatment of febrile episodes in cancer patients with chemotherapy-induced neutropenia. METHODS : A prospective, double-blind, randomized study of cefepime 2g every twelve hours and ceftazime 2g every eight hours was performed in 40 adult neutropenic (absolute neutrophil count 〈500/㎣) cancer patients with fever. RESULTS : Forty patients were evaluable. Median duration of neutropenia was 11.5 days in cefepime and 10.5 days in ceftazidime. Treatment was successful in (60%)(12/20) of cefepime-treated patients and (65%)(13/20) of ceftazi야me-treated patients. Overall mortality was 10%(2/20) of cefepime-treated patients and 15% of ceftazidime-treated patients. CONCLUSIONS : Cefepime appears to be as effective as ceftazidime in the initial treatment of febrile episodes in adults cancer patients with chemotherapy-associated neutropenia of modest duration.

진행성 비소세포폐암에 대한 2차 화학요법으로 paclitaxel과 cisplatin의 제 2상 임상연구

서영태,김봉석,고지영,최동석,최성호,김혜진,안영미,노용호,이경희 영남대학교 의과대학 2004 Yeungnam University Journal of Medicine Vol.21 No.2

gemcitabine과 carboplatin으로 치료받은 경력이 있는 진행성 비소세포폐암 환자 25명을 대상으로 2차 화학요법으로 paclitaxel과 cisplatin을 사용하여 다음과 같은 결과를 확인하였다. 전체 25명 중 5명에서 부분반응이 관찰되었으며, 반응군의 반응지속기간은 2~11개월로 중앙값 4.3개월이었다. 전체 환자의 무진행생존기간은 0~11개월로 중앙값 3.3개월이었으며, 생존기간은 1.3~39개월로 중앙값 7.4개월이었다. 전체 83회의 화학요법 중 WHO 3도의 혈소판감소증이 1회에서만 관찰되었으며, 비혈액학적 부작용도 감내할 만 하였다. 이상의 결과, paclitaxel과 cisplatin 복합화학요법은 진행성 비소세포폐암 환자에서 2차 요법으로 사용하였을 때 부작용이 적으며 효과적인 치료법의 하나로 판단된다. Background: To evaluate the efficacy and safety of paclitaxel and cisplatin against advanced non-small cell lung cancer (NSCLC) as a second-line chemotherapy. Subjects and Methods: Twenty-five patients were enrolled. The patients received 200 mg/㎡ paclitaxel as a 3-hour intravenous infusion and 60 mg/㎡ cisplatin as 30-minute intravenous infusion with vigorous hydration on day 1 every 28 days. The response was assessed every 2 cycles. Results: All 25 patients were assessed for their response and toxicity. Partial responses were observed in 5 patients. The overall response rate was 20%(95% confidence interval, 4%~36%) and the median response duration was 4.5(range, 2-11) months. The median time to progression was 3.3(range, 0-14) months. The median overall survival of all patients was 7.4(range, 1.3-39) months. The hematologic toxicities were minor and easily controlled. Conclusion: The combination chemotherapy of paclitaxel and cisplatin as a second-line treatment has a moderate efficacy with an acceptable toxicity in patients with advanced NSCLC.

Tripledecker 착물, (CpCo)_2(C_4R_4)과 Alkyne과의 반응

嚴在國,李元植,金碩峯,車震淳,李炯秀,李東鎬,金洪碩,沈相喆 대구효성가톨릭대학교 자연과학연구소 1993 基礎科學硏究論集 Vol.1993 No.1

트리플데카 착물류, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt들은 Jonas시약과 2-hexyne 또는 3-hexyne을 실온에서 동량으로 반응시킬때, 50% 이상의 최대 수율이 얻어졌다. 한 종류의 트리플데카 착물인 bis-(η^5-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt(13)는 실온에서 3-hexyne과 반응시키면, 착물 (η^5-cyclopentadienyl)cobalt-acyclopentadiene-μ-(η^4-2,4-cobaltacyclope-ntadiene)(η^5-cyclopentadienyl)cobalt(15)로 이성화되었다. 다른 한 종류의 트리플데카 착물, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,3-dimethyl-2,4-dipropyl-cyclobutadiene)dicobalt(14)를 2-hexyne 과 반응시켰더니 1,3,5-tri-methyl-2,4,6-tripropyl benzene화합물이 생성되었다. The tripledecker complexes, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt were produced by the reaction of Jonas reagent with 2-hexyne and 3-hexyne in the maxi-mum yield(above 50%) when they were reacted in eq-molar amounts at room temperature. A tripledecker complexes,bis-(η^2-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt(13) was isomerized to (η^5-cyclopentadienyl)cobalt-acyclopentadiene-μ-(η^4-2,4-cobaltacyclope-ntadiene)(η^5-cyclopentadienyl)cobalt(15) on reacting with 3-hexyne at room temperature. Another tripledecker complex, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,3-dimethyl-2,4-dipropyl-cyclobutadiene)dicobalt(14) was decomposed to give 1,3,5-trimethyl-2,4,6-trip-ropylbenzene through an intermediate complex by the reaction of 2-hexyne.

한국어판 예일 틱 증상 평가척도 : 신뢰도 및 타당도 연구

정선주,이정섭,유태익,구영진,전성일,김봉석,홍강의 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.5

목 적 : 틱 증상의 심한 정도를 평가하기 위한 도구인 예일 틱 증상 평가척도(Yale Global Tic Severity Scale)를 한국판 가정 평가용 설문지 및 임상 평가용 척도로 개발하기 위하여 본 연구를 시행하였다. 방 법 : 예일 틱 증상 평가척도는 뚜렛 장애 및 기타 틱 장애에서 나타나는 운동틱과 음성틱 각각의 증상의 수, 빈도, 심한 정도, 복합성, 방해 정도 및 장해도를 포괄적으로 평가하도록 고안되어져 있다. 틱 증상을 주소로 정신과외래를 방문한 만 4.3세에서 19세까지의 100명의 환아 및 부모들을 대상으로 한국어로 번역한 예일 틱 증상 평가척도의 가정평가용 설문지를 평가전에 완료하도록 한 후, 면담을 통한 임상평가용 척도를 실시하였으며 수렴타당도 및 변별타당도의 검증을 위해 총괄적인 임상 인상척도-뚜렛 증후군, 강박장애, 주의력결립/과잉운동장애(Clinical Global Impression-TS, OCD, ADHD)를 시행하였다. 결 과 : 자료분석결과 내적일치도, 수렴타당도, 변별타당도 및 검사자간 신뢰도 모두 매우 높게 나타났으며 요인분석상 전 항목척도와 장해도는 운동틱과 음성틱에 해당하는 2개의 요인으로 묶여졌다. 결 론 : 본 연구결과 한국판 예일 틱 증상 평가척도의 높은 타당도 및 신뢰도가 입증되었으며 이는 향후 틱 증상의 객관적인 평가 및 정량화를 위해 유용하게 사용되어질 수 있을 것이다. Objectives : This study was carried out to develop the Korean form of Yale Global Tic Severity Scale(YGTSS)-family & clinical rating version. The severity of motor and phonic tics was rated according to five separate dimensions : number, frequency, intensity, complexity, and interference. Methods : The Korean form of YGTSS was applied to 100 children who visited psychiatric outpatient clinic with chief complaints of tic symptom. Together with YGTSS, Clinical Global Impression for Tourette's syndrome(CGI-TS), Obsessive-Compulsive disorder(CGI-OCD), Attention-Deficit/Hyperactivity Disorder(CGI-ADHD) were administered to all subjects for examining convergent and discriminant validities. Results : We could confirm high internal consistency, convergent and discriminant validities and interrater reliability of YGTSS by analysing data from 100 children with tic disorder. In factor analysis, items were clustered to 2 factors which were identical to motor and phonic tic subscales. Conclusion : The results of this study indicate the Korean form of YGSS is a reliable and valid rating scale for rating tic symptom severity. It can be used to evaluate tic symptom objectively and to quantify the tic severity in the studies for tic disorder.

Research ethics and IRB

( Bong Seog Kim ) 대한피부과학회 2012 대한피부과학회 학술발표대회집 Vol.64 No.3

원발성 양측 부신 비호즈킨 림프종 1 예

김봉석,박성기,이성규,변종훈,김정례,소군호,진교현,김서종,고정석,노용호 대한내과학회 2000 대한내과학회지 Vol.59 No.4

Primary adrenal lymphoma is extremely uncommon. The tumor is accidentally discovered by abdominal ultrasonography(USG), computed tomography(CT) or magnetic resonance imaging (MRI) in patients with nonspecific symptoms and diagnosed at operation or autopsy. In this case, a 60-year-old man was admitted for the evaluation of mild left frank discomfort for two months before admission. The abdominal USG was performed and showed the dense masses in both adrenal glands. The laboratory tests including blood count, chemistry and hormonal tests showed the normal levels except for the basal ACTH level of 108 pg/ml(normal range: 9∼52 pg/ml). The 123I MIBG scan was normal. The bilateral adrenalectomy was done. The tumor was diagnosed as diffuse large B-cell non-Hodgkin's lymphoma(NHL) according to the Revised European-American lymphoma(REAL) classification. He was treated with the adjuvant combination chemotherapy of CHOP(cyclophosphamide, adriamycin, vincristine and prednisolone) but expired due to sepsis after the secod chemotherapy. We describe the first case of primary bilateral adrenal NHL in Korea. Primary adrenal lymphoma should be included in the differential diagnosis of suprarenal mass.(Korean J Med 59:423-427, 2000)

A STUDY ON THE RELATIONSHIP BETWEEN IMPORT PENETRATION, BUSINESS DIVERSIFICATION AND FIRM PERFORMANCE

Seog Soo Kim,Dong Jin Kim,Bong Seon Park 한국철도학회 2007 한국철도학회 학술발표대회논문집 Vol.- No.-

This research attempts to examine the effects of import penetration in an industry on the firms" decision of business diversification and provide an integrative framework including the determinants and results of the business diversification. The research results are as follows. First, the import penetration doesn"t affect the degree of business diversification. Second, the more profitable their core business industry, the lower the degree of business diversification against the import penetration. In addition, both technology-related assets and marketing-related assets are necessary for business diversification when faced with the import penetration. Finally, the inverted U-shaped relationship is supported between the degree of business diversification and firm performance.

Alpha-Fetoprotein이 증가한 만성 간질환의 임상적 특성

김창민,홍석일,조희준,이영현,김봉석,홍원선,이진오,김유철,강태웅,김서운 대한소화기학회 1992 대한소화기학회지 Vol.24 No.4

In an attempt to investigate the factors influencing the specificity of serum level of alphafetoprotein (AFP) for hepatocellular carcinoma, serum levels of AFP were analyzed in 33 patients treated at the department of gastroenterology in the Korea Cancer Center Hospital between January 1989 and December 1991. All patients entered into the study had chronic liver disease with increased serum level of AFP, more than 50 ng/ml. Clinical and; laboratory parameters, such as HBsAg, Anti-HCV, GOT and GPT and image studies with ultraonograpy and computed tomography were sequentially evaluated, every two or three months, in 2Z' patients. Among 33 patients, 30 had liver cirrhosis and three had chronic hepatitis. The median level of serum AFP was 189 ng/ml in 33 patients. Thirty (90.9%) out of 33 patients were positive for HBsAg. Anti-HCV was tested in 14 patients, among whom four (28.6%) were positive. No significant correlation was observed between serum AFP levels and age, sex or positive rates for HBsAg, anti-HCV and cirrhosis. In 32 among 33 patients, no evidence of the development of hepatocellar carcinoma was found after the follow-up period of six to 36 months, when hepatocellar carcinoma teas diagnosed as the space occupying lesion in the liver by ultrasonograpy and computed tomography. Another one patient was also suggested not to develop hepatocellar carcinoma, when clinically evaluated, because liver function and serum AFP level were markedly improved. The follow-up period in 22 patients was determined as the period until the AFP level decreased below the cut-off value, 50 ng/ml, or the end of study period. The serum AFP level and liver function were sequentially tested during the median follow-up period of 7.5 months (range, 3-30), demonstrating that the median serum AFP level significantly decreased from 376.6 ng/ ml to 57.6 ng/ml (p$lt;0.05). With the decrease in serum AFP levels, serum levels of GOT and GPT also decreased (p$lt;0.01). In 20 out of 22 patients, serum level of AFP decreased to less than 50% of the inital level of AFP after the follow-up period. In eight and seven patients, serum levels of AFP decreased to the normal level, less than 20 ng/ml, after tile median follow-up period of 14.5 months (range, 5-30) and 20-49 ng/ml during 4.5 months (range, 3.11), respectively. In two patients, however, change in the serum AFP levels was not observed. In seven patients who had the initial serum AFP level of more than 100 ng/ml and tested serum AFP level and liver function test every two months. serum levels of AFP, GOT and GPT concurrently decreased during the follow-up period. These results demonstrating that serum AFP level increased in benign liver diseases, such as liver cirrhosis and chronic hepatitis, suggest that, in order to increase the clinical usefulness of serum level of AFP for the diagnosis of hepatocellular carcinoma, serum AFP level should be reevaluated for the specificity for hepatocellular carcinoma according to the cut-off value. Because serum AFP level decreased in most of the patients after the follow-up period, tit is also suggested that AFP elevated in benign liver disease might be different from that in hepatocellular carcinoma in molecular characteristics.

Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea

Kim, Bong-Seog,Jin, Jong-Youl,Kwon, Jung Hye,Woo, In Sook,Ko, Yoon Ho,Park, Suk-Young,Park, Hye-Jeong,Kang, Jin Hyung Wiley (Blackwell Publishing) 2018 Asia-Pacific journal of clinical oncology Vol.14 No.5

<P>ConclusionOxycodone/naloxone added to pregabalin or gabapentin provided additional pain relief and symptom control in Korean patients with CIPN, without clinically significant safety concerns.</P>

치료의 전력이 없는 다발성 골수종에 대한 Vincristine, Doxorubicin 및 Dexamethasone(VAD) 복합화학요법의 효과

김경현,박연희,김성환,김봉석,강윤구,류백렬,최병국,임영혁,김태유 대한내과학회 1999 대한내과학회지 Vol.56 No.1

Objective : The combination of vincristine and doxorubicin by continuous infusion was reported to reduce tumor mass more rapidly than standard regimens, which maybe a result of effect on more slowly proliferating plasma cells. We conducted a phase II study to determine the activity and safety of VAD (vincristine, doxorubicin, dexamethasone) chemotherapy, in which vincristine and doxorubicin are administered as a continuous infusion, for previously untreated multiple myeloma. Methods : VAD chemotherapy (vincristine 0.4 mg/day 24 hour-continuous infusion, days 1∼4; doxorubicin 9 mg/m2/day 24 hour-continuous infusion, days 1∼4; dexamethasone 40 mg/day p.o. days 1∼4) was given to eligible patients every 4 weeks and we assessed response and toxicity of the regimen. Results : Between January 1991 and March 1997, total 25 patients entered this trial and 22 were evaluable. The complete response rate was 14%(3/22) and overall response rate was 59%(13/22, 95% C.I.: 38∼80%). The time to response was 1.0∼6.8(median 2.9) months. Progression free survival was 2∼39+(median 11.5) months and the overall survival was 3+∼42+(median 19.7) months. Toxicities of VAD regimen were leukopenia, infection, stomatitis and neurotoxicity, but there was no treatment-related death. Conclusion : VAD chemotherapy was tolerable, but not more active than the alkylating agent-based chemotherapy as a front-line treatment for the patients with multiple myeloma. But, because of its rapid response and relatively mild myelotoxicity, it could play a role for advanced or highly complicated disease and for remission induction before consolidation with high-dose chemotherapy.